JESUS MIGUEL
UNDA URZAIZ
Investigador/a en el periodo 2002-2023
Hospital Universitario La Paz
Madrid, EspañaPublicaciones en colaboración con investigadoras/es de Hospital Universitario La Paz (12)
2022
-
Non-metastatic castration-resistant prostate cancer: management recommendations
Actas Urologicas Espanolas, Vol. 46, Núm. 4, pp. 193-213
2018
-
Actualización del papel de la quimioterapia endovesical en el cáncer de vejiga no músculo-invasivo
Actas Urologicas Espanolas
2016
-
Estudio retrospectivo de diferentes opciones de tratamiento conservador con Bacilo de Calmette-Guèrin en el carcinoma urotelial vesical T1G3: terapia de mantenimiento
Actas Urologicas Espanolas, Vol. 40, Núm. 6, pp. 370-377
2015
-
Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013
European Urology, Vol. 68, Núm. 2, pp. 256-262
-
Sequential combination of mitomycin C plus bacillus calmette-guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: Final outcome of CUETO 93009, a randomized prospective trial
European Urology, Vol. 67, Núm. 3, pp. 508-516
2014
-
Influencia del número real de instilaciones de Bacilo de Calmette-Guérin aplicadas en el pronóstico de los tumores vesicales no músculo-infiltrantes
Actas Urologicas Espanolas, Vol. 38, Núm. 5, pp. 280-284
2013
-
Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study
British Journal of Cancer, Vol. 109, Núm. 1, pp. 121-130
-
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study
British Journal of Cancer, Vol. 108, Núm. 12, pp. 2565-2572
2011
2009
-
LONG-TERM FOLLOW UP OF THE EFFECTIVENESS OF STANDARD DOSE BCG (81 MG. CONNAUGHT STRAIN) COMPARING WITH A THREE FOLD REDUCE DOSE (27 MG.) IN HIGH RISK NON MUSCLE INVASIVE BLADDER CANCER. CUETO GROUP
EUROPEAN UROLOGY SUPPLEMENTS
-
Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model
Journal of Urology, Vol. 182, Núm. 5, pp. 2195-2203
2008
-
Prognostic Factors in Patients with Non-Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: Multivariate Analysis of Data from Four Randomized CUETO Trials
European Urology, Vol. 53, Núm. 5, pp. 992-1002